EXEL
Exelixis Inc

12,215
Mkt Cap
$11.52B
Volume
10,437.00
52W High
$49.62
52W Low
$32.38
PE Ratio
18.09
EXEL Fundamentals
Price
$42.27
Prev Close
$42.98
Open
$43.27
50D MA
$43.62
Beta
0.45
Avg. Volume
2.5M
EPS (Annual)
$1.76
P/B
5.33
Rev/Employee
$1.89M
$9,164.16
Loading...
Loading...
News
all
press releases
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·14h ago
News Placeholder
More News
News Placeholder
Exelixis Q4 Earnings Call Highlights
Exelixis (NASDAQ:EXEL) executives told investors that 2025 was a transformational year marked by continued growth in the company's cabozantinib franchise and accelerating preparations for a potential...
MarketBeat·14h ago
News Placeholder
Exelixis (EXEL) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·15h ago
News Placeholder
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +22.25% and +2.39%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16h ago
News Placeholder
Exelixis (NASDAQ:EXEL) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS
Exelixis (NASDAQ:EXEL - Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts' consensus...
MarketBeat·17h ago
News Placeholder
4 Discounted PEG Value Stocks to Boost Your Portfolio's Health
Discounted PEG screen highlights four value stocks, led by healthcare. One can pick Exelixis, alongside DaVita, Phibro and Allison Transmission.
Zacks·1d ago
News Placeholder
Candriam S.C.A. Grows Stock Holdings in Exelixis, Inc. $EXEL
Candriam S.C.A. increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 18.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission...
MarketBeat·1d ago
News Placeholder
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
Zacks·2d ago
News Placeholder
A Peek at Exelixis's Future Earnings
read more...
Benzinga·2d ago
News Placeholder
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Zacks·2d ago
<
1
2
...
>

Latest EXEL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.